Huseyin Istanbullu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Huseyin Istanbullu has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Gulsah Bayraktar
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ege University, 35040 Izmir, Turkey
6 shared publications Merve Saylam
İzmir Katip Çelebi University, Turkey
4 shared publicationsErcin Erciyas
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ege University, Bornova, Izmir, Turkey
3 shared publicationsIbrahim Cavus
Manisa Celal Bayar University, Turkey
3 shared publicationsAhmet Ozbilgin
Manisa Celal Bayar University, Turkey
2 shared publications- Ezgi Turunc
Department of Biochemistry, Faculty of Pharmacy, Ege University, Bornova, Izmir, Turkey
2 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Pharmaceutical Sciences
- Vol. 62
Biological evaluation of thiazolopyrimidine derivatives as novel heterocyclic compounds against promastigote and amastigote-like forms of Leishmania infantum and Leishmania tropica
Leishmaniasis is an underfunded neglected disease that affects 12 million people mainly living in developing countries. Herein, based on the data we obtained in our previous study, we designed and synthesized novel thiazolo[5,4-d]pyrimidine derivatives and evaluated their in vitro antileishmanial bio-activity. The compounds were synthesized, and their structures were elucidated. Then, their anti-leishmanial activities were tested using both promastigote and amastigote-like forms of L. tropica and L. infantum parasites. Additionally, we evaluated the in silico physicochemical properties and the structure-activity relationships of the compounds. Compound 4-chloro-N-[5-(4-hydroxypiperidin-1-yl)miazolo[5,4-d]pyrimidin-2-yl]benzamide (A1), with IC50 values of 43.58 μΜ and 41.45 μΜ against L. tropica and L. infantum promastigotes, respectively, and 70.02 μΜ and 77.13 μΜ against L. tropica and L. infantum axenic amastigote-like forms, was found to be the most active compound in both assays. Compound A1 also exhibited the lowest iLogP value among the compounds, suggesting high passive gastrointestinal absorption. Based on both in vitro assays and in silico properties, compound A1 demonstrates significant anti-parasitic activity and serves as a promising lead for the development of new antileishmanial agents.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Pharmaceutical Sciences
- Vol. 62
Open AccessBiological evaluation of thiazolopyrimidine derivatives as novel heterocyclic compounds against promastigote and amastigote-like forms of Leishmania infantum and Leishmania tropica
Leishmaniasis is an underfunded neglected disease that affects 12 million people mainly living in developing countries. Herein, based on the data we obtained in our previous study, we designed and synthesized novel thiazolo[5,4-d]pyrimidine derivatives and evaluated their in vitro antileishmanial bio-activity. The compounds were synthesized, and their structures were elucidated. Then, their anti-leishmanial activities were tested using both promastigote and amastigote-like forms of L. tropica and L. infantum parasites. Additionally, we evaluated the in silico physicochemical properties and the structure-activity relationships of the compounds. Compound 4-chloro-N-[5-(4-hydroxypiperidin-1-yl)miazolo[5,4-d]pyrimidin-2-yl]benzamide (A1), with IC50 values of 43.58 μΜ and 41.45 μΜ against L. tropica and L. infantum promastigotes, respectively, and 70.02 μΜ and 77.13 μΜ against L. tropica and L. infantum axenic amastigote-like forms, was found to be the most active compound in both assays. Compound A1 also exhibited the lowest iLogP value among the compounds, suggesting high passive gastrointestinal absorption. Based on both in vitro assays and in silico properties, compound A1 demonstrates significant anti-parasitic activity and serves as a promising lead for the development of new antileishmanial agents.
- Open Access
- 14 June 2025
- Published by Izmir Katip Celebi University Faculty of Health Sciences in İzmir Katip Çelebi Üniversitesi Sağlık Bilimleri Fakültesi Dergisi
- Vol. 10 (2) , 229-237
Evaluation of Antimicrobial and Antibiofilm Effects of Kojic Acid Derivatives against Bacteria and Fungi
Objective: In this study, it was aimed to investigate the antibacterial and antifungal activities of kojic acid derivatives against Gram-negative bacteria (Pseudomonas aeruginosa and Escherichia coli), Gram-positive bacteria (Enterococcus faecalis and Staphylococcus aureus) and fungal strain (Candida albicans). Material and Methods: Antimicrobial activity profiles of the compounds were investigated by microdilution and disk diffusion method. Antibiofilm activities were investigated by spectrophotometric microplate method including crystal violet staining. Moreover, the impact of the compounds on both biofilm and cells was also clarified via scanning electron microscopy (SEM). Results: Minimum inhibitory concentration values were found between 16 μg/mL to 1024 μg/mL. The most potent substance, 3b bearing 3,4- dichlorobenzylpiperazine moiety, has been shown to have inhibitory effects at 16-64 μg/mL concentrations. It was determined that 3a and 3b had stronger inhibitory effects than the other substances against C. albicans. In addition, antibacterial activity was discovered to be greater against Gram-positive strains than Gram-negative. It was also shown by SEM that compound 3b caused significant deformation on the cell wall and membrane of E. faecalis strain and inhibited the biofilm structures of S. aureus and E. coli strains. Conclusion: Kojic acid derivatives were found to inhibit the growth of both bacterial and fungal pathogens at low concentrations. It was also shown that kojic acid derivatives were able to decrease biofilm formation. It is thought that, this will be a favourable scenario for novel therapeutic candidates since more novel compounds will be created, and the inhibitory mechanism will be explored in various research including phenotypic and genotypic experiments.
- 14 June 2025
- Published by Izmir Katip Celebi University Faculty of Health Sciences in İzmir Katip Çelebi Üniversitesi Sağlık Bilimleri Fakültesi Dergisi
- Vol. 10 (2) , 229-237
Open AccessEvaluation of Antimicrobial and Antibiofilm Effects of Kojic Acid Derivatives against Bacteria and Fungi
Objective: In this study, it was aimed to investigate the antibacterial and antifungal activities of kojic acid derivatives against Gram-negative bacteria (Pseudomonas aeruginosa and Escherichia coli), Gram-positive bacteria (Enterococcus faecalis and Staphylococcus aureus) and fungal strain (Candida albicans). Material and Methods: Antimicrobial activity profiles of the compounds were investigated by microdilution and disk diffusion method. Antibiofilm activities were investigated by spectrophotometric microplate method including crystal violet staining. Moreover, the impact of the compounds on both biofilm and cells was also clarified via scanning electron microscopy (SEM). Results: Minimum inhibitory concentration values were found between 16 μg/mL to 1024 μg/mL. The most potent substance, 3b bearing 3,4- dichlorobenzylpiperazine moiety, has been shown to have inhibitory effects at 16-64 μg/mL concentrations. It was determined that 3a and 3b had stronger inhibitory effects than the other substances against C. albicans. In addition, antibacterial activity was discovered to be greater against Gram-positive strains than Gram-negative. It was also shown by SEM that compound 3b caused significant deformation on the cell wall and membrane of E. faecalis strain and inhibited the biofilm structures of S. aureus and E. coli strains. Conclusion: Kojic acid derivatives were found to inhibit the growth of both bacterial and fungal pathogens at low concentrations. It was also shown that kojic acid derivatives were able to decrease biofilm formation. It is thought that, this will be a favourable scenario for novel therapeutic candidates since more novel compounds will be created, and the inhibitory mechanism will be explored in various research including phenotypic and genotypic experiments.
- Open Access
- 29 April 2025
- Published by MDPI AG in Drugs and Drug Candidates
- Vol. 4 (2) , 20
Probing Redox Responses and DNA Interactions in Drug Discovery
Background/Objectives: The thiazolo [5,4-d]pyrimidine scaffold is a class of drugs known for its anticancer, antitumor, anti-inflammatory, and antimicrobial properties. In this study, the electrochemical properties of novel thiazolo [5,4-d]pyrimidine derivatives and their interactions with DNA were characterized for the first time using voltammetric methods. Determining the interactions of new drug candidate molecules with DNA is crucial for drug development studies and is the main objective of this research. Methods: Both molecules were immobilized on the surface of the electrodes by passive adsorption, and their electrochemical properties were determined by voltammetric methods through reduction currents. Their interactions with DNA were carried out in the solution phase and examined by the changes in the oxidation peak potential and current of the guanine base. Results: For both molecules, it was determined that the electrochemical reduction processes are diffusion-controlled and irreversible, with an equal number of protons and electrons being transferred during this process. The detection limits for TP-NB (4-chloro-N-(5-chlorothiazolo [5,4-d]pyrimidin-2-yl)-3-nitrobenzamide) and TP-PC (1-(2-(4-(4-carbamoylpiperidin-1-yl)-3-nitrobenzamido)thiazolo [5,4-d]pyrimidin-5-yl)piperidine-4-carboxamide) were determined to be 12 µg/mL and 16 µg/mL, respectively. As a result of the interaction between both molecules with DNA, the guanine oxidation current decreased. It was found that TP-NB could act as an intercalator, while TP-PC could affect DNA electrostatically, both showing toxic effects on DNA. Conclusions: An electrochemical method was developed for the rapid, cost-effective, and sensitive detection of both molecules and their DNA interactions. Both compounds exhibited notable affinity towards DNA, as evidenced by significant changes in oxidation peak currents, shifts in peak potentials, and calculated toxicity values. These findings suggest their potential use as DNA-interacting drugs, such as anticancer and antimicrobial agents. Our study offers a quick, cost-effective, and reliable electrochemical approach for the evaluation of drug–DNA interactions.
- 29 April 2025
- Published by MDPI AG in Drugs and Drug Candidates
- Vol. 4 (2) , 20
Open AccessProbing Redox Responses and DNA Interactions in Drug Discovery
Background/Objectives: The thiazolo [5,4-d]pyrimidine scaffold is a class of drugs known for its anticancer, antitumor, anti-inflammatory, and antimicrobial properties. In this study, the electrochemical properties of novel thiazolo [5,4-d]pyrimidine derivatives and their interactions with DNA were characterized for the first time using voltammetric methods. Determining the interactions of new drug candidate molecules with DNA is crucial for drug development studies and is the main objective of this research. Methods: Both molecules were immobilized on the surface of the electrodes by passive adsorption, and their electrochemical properties were determined by voltammetric methods through reduction currents. Their interactions with DNA were carried out in the solution phase and examined by the changes in the oxidation peak potential and current of the guanine base. Results: For both molecules, it was determined that the electrochemical reduction processes are diffusion-controlled and irreversible, with an equal number of protons and electrons being transferred during this process. The detection limits for TP-NB (4-chloro-N-(5-chlorothiazolo [5,4-d]pyrimidin-2-yl)-3-nitrobenzamide) and TP-PC (1-(2-(4-(4-carbamoylpiperidin-1-yl)-3-nitrobenzamido)thiazolo [5,4-d]pyrimidin-5-yl)piperidine-4-carboxamide) were determined to be 12 µg/mL and 16 µg/mL, respectively. As a result of the interaction between both molecules with DNA, the guanine oxidation current decreased. It was found that TP-NB could act as an intercalator, while TP-PC could affect DNA electrostatically, both showing toxic effects on DNA. Conclusions: An electrochemical method was developed for the rapid, cost-effective, and sensitive detection of both molecules and their DNA interactions. Both compounds exhibited notable affinity towards DNA, as evidenced by significant changes in oxidation peak currents, shifts in peak potentials, and calculated toxicity values. These findings suggest their potential use as DNA-interacting drugs, such as anticancer and antimicrobial agents. Our study offers a quick, cost-effective, and reliable electrochemical approach for the evaluation of drug–DNA interactions.
- 19 April 2025
- Published by Wiley in Chemistry & Biodiversity
- p. e202500205
Novel Triazolopyrimidinone Compounds as Inhibitors of Adipocyte Fatty Acid–Binding Protein (FABP4)
Metabolic syndrome, characterized by a combination of high blood pressure, elevated blood glucose levels, high triglycerides, low HDL cholesterol, and abdominal obesity, significantly increases the risk of coronary heart disease, diabetes, and stroke. Fatty acid–binding proteins (FABPs), particularly FABP4, play a crucial role in these processes, serving as lipid chaperones that regulate lipid responses in adipocytes and macrophages. Recent advances in FABP4 inhibitor (FABP4i) development have shown potential in improving insulin resistance and related metabolic conditions in experimental models. The design of new FABP4i compounds, particularly those based on the [1,2,4]triazolo[1,5‐a]pyrimidin‐7(3H)‐one core structure, offers promising strategies for treating obesity‐related metabolic disorders. In this study, a group of triazolopyrimidine‐7‐on derivatives was synthesized, and their FABP4i activity was evaluated. Compound 1 was found to be the most active, with one‐third of the activity of arachidonic acid.
- 19 April 2025
- Published by Wiley in Chemistry & Biodiversity
- p. e202500205
Novel Triazolopyrimidinone Compounds as Inhibitors of Adipocyte Fatty Acid–Binding Protein (FABP4)
Metabolic syndrome, characterized by a combination of high blood pressure, elevated blood glucose levels, high triglycerides, low HDL cholesterol, and abdominal obesity, significantly increases the risk of coronary heart disease, diabetes, and stroke. Fatty acid–binding proteins (FABPs), particularly FABP4, play a crucial role in these processes, serving as lipid chaperones that regulate lipid responses in adipocytes and macrophages. Recent advances in FABP4 inhibitor (FABP4i) development have shown potential in improving insulin resistance and related metabolic conditions in experimental models. The design of new FABP4i compounds, particularly those based on the [1,2,4]triazolo[1,5‐a]pyrimidin‐7(3H)‐one core structure, offers promising strategies for treating obesity‐related metabolic disorders. In this study, a group of triazolopyrimidine‐7‐on derivatives was synthesized, and their FABP4i activity was evaluated. Compound 1 was found to be the most active, with one‐third of the activity of arachidonic acid.
- Open Access
- 9 October 2024
- Published by Elsevier in European Journal of Medicinal Chemistry Reports
- Vol. 12
Biological properties and in silico studies of thiazolopyrimidine derivatives active against visceral and cutaneous Leishmania spp. amastigote forms
- 9 October 2024
- Published by Elsevier in European Journal of Medicinal Chemistry Reports
- Vol. 12
Open AccessBiological properties and in silico studies of thiazolopyrimidine derivatives active against visceral and cutaneous Leishmania spp. amastigote forms
- 5 August 2024
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 15 (17) , 8689-8699
Cinnamon extracts, trans-cinnamaldehyde and trans-cinnamic acid inhibit HDAC 1 activity
Essential oil and 70% ethanol extract of Cinnamomum cassia bark can be evaluated to be used in products against HDAC 1 related diseases.
- 5 August 2024
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 15 (17) , 8689-8699
Cinnamon extracts, trans-cinnamaldehyde and trans-cinnamic acid inhibit HDAC 1 activity
Essential oil and 70% ethanol extract of Cinnamomum cassia bark can be evaluated to be used in products against HDAC 1 related diseases.
- 28 November 2023
- Published by Istanbul University in İstanbul Journal of Pharmacy
- Vol. 53 (3) , 287-293
The investigation of drug repurposing for HDAC1 inhibitory effects by in silico and in vitro methods
- 28 November 2023
- Published by Istanbul University in İstanbul Journal of Pharmacy
- Vol. 53 (3) , 287-293
The investigation of drug repurposing for HDAC1 inhibitory effects by in silico and in vitro methods
- Open Access
- 10 November 2023
- Published by IntechOpen
Quinazoline and its Derivatives: Privileged Heterocyclic Scaffolds in Antileishmanial Drug Discovery
Leishmaniasis is a parasitic disease caused by protozoa belonging to the genus Leishmania. Over one billion people are living in areas endemic to leishmaniasis and are at risk of infection. Each year, more than one million new cases are reported. Although few drugs are available for the treatment of leishmaniasis, none of them are ideal due to their high resistance and toxicity risk. Many compounds with quinazoline scaffold were synthesized and reported to have promising antiparasitic and antileishmanial activities. This review aims to evaluate the reported antileishmanial activities of quinazoline and its derivatives with a special focus on their structure-activity relationships.
- 10 November 2023
- Published by IntechOpen
Open AccessQuinazoline and its Derivatives: Privileged Heterocyclic Scaffolds in Antileishmanial Drug Discovery
Leishmaniasis is a parasitic disease caused by protozoa belonging to the genus Leishmania. Over one billion people are living in areas endemic to leishmaniasis and are at risk of infection. Each year, more than one million new cases are reported. Although few drugs are available for the treatment of leishmaniasis, none of them are ideal due to their high resistance and toxicity risk. Many compounds with quinazoline scaffold were synthesized and reported to have promising antiparasitic and antileishmanial activities. This review aims to evaluate the reported antileishmanial activities of quinazoline and its derivatives with a special focus on their structure-activity relationships.
- Open Access
- 4 January 2023
- Published by IntechOpen
Fused Pyridine Derivatives: Synthesis and Biological Activities
Five-membered heteroaromatic ring fused pyridine derivatives are of increasing interest in drug design and medicinal chemistry. The structural similarity of many drugs (especially antiviral and anticancer ones) with DNA bases such as adenine and guanine is a key factor to explain their effectiveness. Apart from these, it is also found in the structures of substances with antituberculosis, antibacterial, antifungal, anti-inflammatory, and antimalarial activities. Another advantage of this group of compounds is their positive contribution to solubility, polarity, lipophilicity, and hydrogen bonding capacity properties of the compounds they are incorporated into. In this chapter, various bioactivities of fused pyridine derivatives will be categorized and summarized.
- 4 January 2023
- Published by IntechOpen
Open AccessFused Pyridine Derivatives: Synthesis and Biological Activities
Five-membered heteroaromatic ring fused pyridine derivatives are of increasing interest in drug design and medicinal chemistry. The structural similarity of many drugs (especially antiviral and anticancer ones) with DNA bases such as adenine and guanine is a key factor to explain their effectiveness. Apart from these, it is also found in the structures of substances with antituberculosis, antibacterial, antifungal, anti-inflammatory, and antimalarial activities. Another advantage of this group of compounds is their positive contribution to solubility, polarity, lipophilicity, and hydrogen bonding capacity properties of the compounds they are incorporated into. In this chapter, various bioactivities of fused pyridine derivatives will be categorized and summarized.